Manager TitleAgeSince
Chief Executive Officer 53 30/08/2022
Director of Finance/CFO 55 02/05/2023
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Chairman 71 15/04/2021
Director/Board Member 63 15/04/2021
Director/Board Member 68 15/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+8.00% - - 15.15L
-0.32%-5.68%-4.19%+9.81% 4.61TCr
-2.08%-3.57%+402.72%+533.09% 4.36TCr
+0.12%-5.27%+39.94%+20.50% 4.24TCr
-2.62%-5.76%+8.88%+77.44% 3.89TCr
-1.26%-3.37%+11.87%+40.55% 3.22TCr
+0.16%-3.65% - - 1.72TCr
-0.54%-1.72%+22.34%+115.10% 1.63TCr
+0.54%-1.95%+11.41%+31.60% 1.43TCr
-1.92%-6.94%+78.12%+36.68% 1.3TCr
Average -0.20%-4.70%+71.38%+108.10% 2.93TCr
Weighted average by Cap. -1.00%-5.04%+86.43%+128.39%
Logo Amniotics AB
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Employees
4
  1. Stock Market
  2. Stocks
  3. AMNI Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!